Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia

Translated title of the contribution: Cardiovascular calcification and atherosclerosis accelerated during uremia

Mario Cozzolino, Alessandra Butti, Giusy Chiarelli, Lisa Rocca-Rey, Gaia Santagostino, Maurizio Gallieni, Diego Brancaccio

Research output: Contribution to journalArticle


Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.

Original languageItalian
Pages (from-to)25-28
Number of pages4
JournalItalian Heart Journal Supplement
Issue number1
Publication statusPublished - Jan 2005


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cozzolino, M., Butti, A., Chiarelli, G., Rocca-Rey, L., Santagostino, G., Gallieni, M., & Brancaccio, D. (2005). Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. Italian Heart Journal Supplement, 6(1), 25-28.